Troponin as a marker of myocardiac damage in drug-induced cardiotoxicity

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 457-472

  Adamcová, Michaela ^a   Šterba, Martin ^a   Šimunek, Tomáš ^a   Potácová, Anna ^a   Popelová, Olga ^a   Mazurová, Yvona ^a   Geršl, Vladimír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

sympathomimetics; Anthracyclines; Antineoplastic drug; Biochemical marker; Cardiac troponins T and I (cTnT, cTnI); Cardioprotection; Cardiotoxicity

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRAQUINONE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; COCAINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; IMATINIB; IRON CHELATING AGENT; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PYRIDOXAL ISONICOTINOYLHYDRAZONE; RAZOXANE; TROPONIN I; TROPONIN T; UTERUS SPASMOLYTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ALCOHOL ABUSE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DRUG POTENTIATION; HEART ARRHYTHMIA; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; IMMUNOASSAY; LABORATORY TEST; MYOCARDITIS; NONHUMAN; PATIENT MONITORING; PERICARDITIS; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; STANDARDIZATION; SUBSTANCE ABUSE; TOCOLYSIS;

DRUG EVALUATION, PRECLINICAL; HEART; HUMANS; IMMUNOASSAY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TOXICITY TESTS; TROPONIN I; TROPONIN T;

EID: 19444383085     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.457     Document Type: Review

References (135)

1. CASARETT LJ, WATKINS JB, KLASSEN CD, DOULL J: Toxic responses of the heart and vascular systems. In: Casarett & Doull's Toxicology - The Basic Science of Poisons (5th edition). Klaassen CD (Ed.), McGraw-Hill Professional, New York (1998):487-500.
2. GHARIB MI, BURNETT AK: Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.Eur. J. Heart Fail. (2002) 4(3):235-242.
3. YEH ETH, TONG AT, LENIHAN DJ et al.: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation (2004) 109(25):3122-3131.
4. TOMITA S, ISHIDA M, NAKATANI T et al.: Bone marrow is a source of regenerated cardiomyocytes in doxorubicin-induced cardiomyopathy and granulocyte colony-stimulating factor enhances migration of bone marrow cells and attenuates cardiotoxicity of doxorubicin under electron microscopy. J. Heart Lung Transplant. (2004) 23(5):577-584.
5. KARMEN A, WROBLEWSKI F, LADUE JS: Transaminase activity:in human blood. J. Clin. Invest. (1954) 34:126-133.
6. PANTEGHINI M, APPLE FS, CHRISTENSON RH, DATI F, MAIR J, WU AH: Proposals from the IFCC Committee on markers of cardiac damage (C-SMCD): recommendations on the use of biochemical markers of cardiac damage in acute coronary syndromes. Scan J. Clin. Lab. Invest. (1999) 59(230):103-112.
7. Joint European Society of Cardiology/American College of Cardiology Committee: Myocardial infarction redefined - a consensus document of the joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J. Am. Coll. Cardiol. (2000) 36:959.
8. MISSOV E, CALZOLARI C, PAU B: Circulating cardiac troponin I in severe congestive heart failure Circulation (1997) 96:2953-2958
9. MAIR J: Progress in myocardial damage detection: New biochemical markers for clinicians. Crit. Rev. Cl. Lab. Sci. (1997) 34(1):1-66.
10. LA VECCHIA L, MEZZENA G, OMETTO R et al.: Detectable serum troponin I in patients with heart failure of nonmyocardial ischemic origin. Am. J. Cardiol. (1997) 80:88.
11. WALLACE KB, HAUSNER E, HERMAN E et al.: Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol. Pathol. (2004) 32:106-121.
12. EBASHI S, ENDO M, OHTSUKI I: Control of muscle contraction. Q. Rev. Biophys. (1969) 2:351-384.
13. GREASER ML, YAMAGUCHI M, BREKKE C, POTTER J, GERGELY J: Troponin subunits and their interactions. Cold Spring Harbour Symp. Quant. Biol. (1972) 37:235-244.
14. PERRY SV: Troponin I: Inhibitor or facilitator. Mol. Cell. Biochem. (1999) 190:9-32.
15. SOLARO RJ: Troponin C - troponin I interactions and molecular signalling in cardiac myofilaments. Adv. Exp. Med. Biol. (1995) 382:109-115.
16. SOLARO RJ, RARICK HM: Troponin and tropomyosin: Proteins that switch on and tune in the activity of cardiac myofilaments. Circ. Res. (1998) 83:471-480.
17. WILKINSON JM, GRAND RJA: Comparison of amino acid sequence of troponin I from different striated muscles. Nature (1978) 271:31-35.
18. PEARLSTONE J, CARPENTER M, SMILLIE L: Amino acid sequences of rabbit cardiac troponin T. J. Biol. Chem. (1986) 261:16795-16810.
19. PHARMACEK MS, LEIDEN JM: Structure, function and regulation of troponin C. Circulation (1991) 84:991-1003.
20. HOLT DW: Pre-clinical application of markers of myocardial damage. In: Myocardial damage. Developments in Cardiovascular Medicine (vol. 205). Kaski JC and Holt DW (Eds.) Kluwer Academic Publishers (1998):201-210.
21. WU AHB: Role of serum biochemical markers in clinical trials. In: Myocardial damage. Developments in Cardiovascular Medicine (vol. 205). Kaski JC and Holt DW (Eds.), Kluwer Academic Publishers (1998):189-198.
22. SPARANO JA, WOLFF AC, BROWN DL: Troponins for predicting cardiotoxicity from cancer therapy. Lancet (2000) 356(9246):1947-1948.
23. SPARANO JA, BROWN DL, WOLFF AC: Predicting cancer therapy-induced cardiotoxicity - The role of troponins and other markers. Drug Saf. (2002) 25(5):301-311.
24. HERMAN EH, FERRANS VJ: The use of cardiac biomarkers for the detection of drug-induced myocardial damage, In: Markers in Cardiology: Current and future clinical applications. Adams JE III, Apple FS, Jaffe AS, Wu AHB (Eds.) Armonk, NY, Futura Publishing Company, Inc. (2001) 211-234.
25. HERMAN EH, LIPSHULTZ SE, FERRANS VJ: The use of cardiac markers to detect myocardial damage induced by chemotherapeutic agents. In: Cardiac Markers. Wu AHB (Ed.) Humana Press, Inc., Totowa, NJ (2003):87-109.
26. TOWNSEND PJ, FARZA H, MACGEOCH C et al.: Human cardiac troponin T identification of fetal isoforms and assignment of the TNNT2 locus to chromosome lq. Genomics (1994) 21:311-316.
27. VALLINS WJ, BRAND NJ, DABHADE N, BUTLER-BROWNE G, YACOUB MH, BARTON PJR: Molecular cloning of human cardiac troponin I using polymerase chain reaction. FEBS Lett. (1990) 270:57-61.
28. SASSE S, BRAND NJ, KYPRIANOU P et al. Troponin I gene expression during human cardiac development and in endstage heart failure. Circ. Res. (1993) 72:932-938.
29. RICCHIUTI V, VOSS EM, NEY A, ODLAND M, ANDERSON PAW, APPLE FS: Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin. Chem. (1998) 44:1919-1924.
30. BODOR GS, SURVANT L, VOSS EM, SMITH S, PORTERFIELD D, APPLE FS: Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin. Chem. (1997) 43(3):476-484.
31. DEAN KJ: Biochemistry and molecular biology of troponin I and T. In: Cardiac Markers. Wu AHB (Ed.), Humana Press, Inc., Totowa, NJ (1998):193-204.
32. VOSS EM; SHARKEY SW, GERNERT AE et al.: Human and canine cardiac troponin T and creatine kinase MB distribution in normal and diseased myocardium: Infarct sizing using serum profiles. Arch. Pathol. Lab. Med. (1995) 119:799-806.
33. WU AHB: Markers of ischemia. In: Cardiac Markers. Wu AHB (Ed.), Humana Press, Inc., Totowa, NJ (2003):250-271.
34. KATUS HA, REMPPIS A, NEUMANN FJ et al.: Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation (1991) 83:902-912.
35. KATUS HA, REMPPIS A, SCHEFFOLD T, DIEDERICH KH, KUBLER W: Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am. J. Cardiol. (1991) 67:1360-1367.
36. MAIR J, GENSER N, MORANDELL D: Cardiac troponin I in the diagnosis of myocardial injury and infarction. Clin. Chim. Acta (1996) 245:19-38.
37. MAIR J, WAGNER I, PUSCHENDORF B et al. Cardiac troponin I to diagnose myocardial injury. Lancet (1993) 341:838-839.
38. O'BRIEN PJ, DAMERON GW, BECK ML et al.: Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals. Lab. Anim. Science (1997) 47(5):486-495.
39. O'BRIEN PJ, DAMERON GW, BECK ML et al.: Differential reactivity of cardiac and skeletal muscle from various species in two generations of cardiac troponin immunoassays. Res. Vet. Sci. (1998) 65(2):135-137.
40. FREDERICKS S, MERTON GK, LERENA MJ, HEINING P, CARTER ND, HOLT DW: Cardiac troponins and creatine kinase content of striated muscle in common laboratory animals. Clin. Chim. Acta (2001) 304:65-74.
41. CALABRESI P, CHABNER BA: Chemotherapy of neoplastic diseases. In: Goodman Gilman's The pharmacological basis of therapeutics (10th edition). Hardman JG, Limbird LE (Eds.), New York: McGraw-Hill (2001):1381-1459.
42. TAN C, TASAKA H, YU KP, MURPHY ML, KARNOFSKY DA: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer (1967) 20:333-353.
43. VON HOFF DD, ROZENCWEIG M, PICCART M: The cardiotoxicity of anticancer agents. Semin. Oncol. (1982) 9:23-33.
44. HRDINA R, GERŠL V, KLIMTOVÁ I, ŠIMUNEK T, MACHACKOVÁ J, ADAMCOVÁ M: Anthracycline - induced cardiotoxicity. Acta medica (Hradec Králové) (2000) 43(3):75-82.
45. STEINHERZ LJ, STEINHERZ PG, TAN CT, HELLER G, MURPHY ML: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA (1991) 266:1672-1677.
46. SEINO Y, TOMITA Y, NAGAE Y et al.: Cardioprotective effects of ACE-inhibitor (Cilazapril) on adriamycin cardiotoxicity in spontaneously hypertensive rats. Circulation (1993) 88:I633.
47. HERMAN EH, ZHANG J, LIPSHULTZ SE et al.: Correlation between serum levels of cardiac troponin T and severity of the chronic cardiomyopathy induced by doxorubicin. J. Clin. Oncol. (1999) 17(7):2237-2243.
48. HERMAN EH, LIPSHULTZ SE, RIFAI N et al.: Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res. (1998) 58(2):195-197.
49. GERŠL V, HRDINA R: Noninvasive polygraphic changes in daunorubicin-induced cardiomyopathy in rabbits. Sbor. ved. praci LF UK Hradec Králové(1994) 37(2):49-55.
50. ADAMCOVÁ M, GERŠL V, HRDINA R et al.: Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits, J. Cancer Res. Clin. Oncol. (1999) 125(5):268-274.
51. ŠIMUNEK T, KLIMTOVǍ I, KAPLANOVǍ J et al.: Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. Eur. J. Heart Failure (2004) 6:377-387.
52. ŠIMUNEK T, KLIMTOVǍ I, ADAMCOVǍ M et al.: Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy. Cancer Chemother. Pharmacol. (2003) 52:431-434.
53. KOH E, NAKAMURA T, TAKAHASHI H: Troponin T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ. J. (2004) 68 (2):163-167.
54. HERMAN EH, FERRANS VJ: Preclinical animal models of cardiac protection from anhracycline-induced cardiotoxicity. Semin. Oncol. (1998) 25:15-21.
55. BERTINCHANT JP, POLGE A, JUAN JM et al.: Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy in rats, and their relationship with echocardiographic and histological findings. Clin. Chim. Acta (2003) 329(1-2):39-51.
56. ADAMCOVÁ M, GERŠL V, MACHACKOVÁ J et al.: Troponins in experimental studies. Acta medica (Hradec Krélové) (2002) 45(1):29-32
57. GENSER N, FINK FM, MAIR J, DENGG K, ELLENMUTER H, PUSCHENDORF B: Plasma concentration of creatine kinase MB mass and troponin T in children receiving anthracycline chemotherapy. Clin. Chem. (1993) 39:1170a.
58. RADERER M, KORNEK G, WEINLANDER G, KASTNER J: Serum troponin T levels in adults undergoing anthracycline therapy. J. Nat. Cancer Inst. (1997) 89(2):179.
59. FINK FM, GENSER N, FINK CH, FALK M, MAIR J: Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med. Pediatr. Oncol. (1995) 25:185-189.
60. KISMET E, VARAN A, AYABAKAN C, ALEHAN D, PORTAKAL O, BUYUKPAMUKCU M: Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr. blood Cancer (2004) 42(3):220-224.
61. LIPSHULTZ SE, RIFAI N, SALLAN SE et al.: Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation (1997) 96:2641-2648
62. AUNER HW, TINCHON C, LINKESCH W et al.: Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol. (2003) 82(4):218-222.
63. MATHEW P, SUAREZ W, KIP K et al.: Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest. (2001) 19:352-359.
64. SEDKY LM, HAMADA E, SELIM H et al.: The value of troponin I measurement in assessment of anthracycline induced cardiotoxicity among breast cancer patients. Proc. Am. Soc. Clin. Oncol. (2001) 20:6b.
65. CARDINALE D, SANDRI MT, MARTINONI A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol. (2000) 36:517-522.
66. MISSOV E, CALZOLARI C, DAVY JM, LECLERCQ F, ROSSI M, PAU B: Cardiac troponin I in patients with hematologic malignancies. Cor. Artery Dis. (1997) 8:537-541.
67. CARDINALE D, SANDRI MT, COLOMBO A et al.: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation (2004) 109(22):2749-2754.
68. LIPSHULTZ SE, SALLAN S, DALTON V et al.: Elevated serum cardiac troponin T as a marker for active cardiac injury during therapy for childhood acute lymphoblastic leukemia (ALL). Proc. Am. Soc. Clin. Oncol. (2001) 18:568a.
69. LIPSHULTZ SE, RIFAI N, DALTON VM et al.: The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N. Engl. J. Med. (2004) 351:145-153.
70. LINK G, TIROSH R, PINSON A, HERSHKO C: Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J. Lab. Clin. Med. (1996) 127(3):272-278.
71. HERMAN EH, ZHANG J, RIFAI N et al.: The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin-and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. (2001) 48:297-304.
72. ADAMCOVÁ M, GERŠL V, MACHACKOVÁ J, HRDINA R, KLIMTOVǍ I, ŠIMUNEK T: Troponins for predicting cardiotoxic or cardioprotective effects of new drugs. In: Advances in recent cardiovascular research - Proceedings of the 22nd European section Meeting of ISHR Szeged (Hungary). Varró A, Végh A (Eds.), Monduzzi Editore, Italy (2002):87-91.
73. ADAMCOVÁ M, PELOUCH V, GERŠL V et al.: Protein profiling in daunorubicin-induced cardiomyopathy. Gen. Physiol. Biophys. (2003) 22(3):411-419.
74. ADAMCOVÁ M, MACHACKOVÁ J, GERŠL V et al.: Cardiac troponin T following repeated administration of pyridoxal isonicotinoyl hydrazone in rabbits. Phys. Res. (2002) 51(5):443-448.
75. ŠIMUNEK T, KLIMTOVÁ I, KAPLANOVÁ J et al.: Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol. Res. (2005) 51:223-231.
76. FELESZKO W, MLYNARCZUK I, BALKOWIEC-ISKRA EZ et al.: Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Clin. Cancer Res. (2000) 6(5):2044-2052.
77. WISEMAN LR, SPENCER CM: Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs (1998) 56:385-403.
78. ARLIN ZA, SILVER R, CASSILETH P et al.: Phase I-II trial of mitoxantrone in acute leukemia. Cancer Treat. Rep. (1985) 69:61-64.
79. DE FORNI M, MALET-MARTINO MC, JAILLAIS P et al.: Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J. Clin. Oncol. (1992) 10:1795-1801.
80. OZTOP I, GENCER M, OKAN T et al.: Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jap. J. Clin. Oncol. (2004) 34(5):262-268.
81. NAG SM, BRISCOE K, DESOUZA P: A pilot study of troponin T as a prognostic marker in patients treated with 5-fluorouracil. Proc. Am. Soc. Clin. Oncol. (2001) 20:344b.
82. GOLDBERG MA, ANTIN JH, GUINAN EC, RAPPEPORT JM: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood (1986) 68:1114-1118.
83. AUNER HW, TINCHON C, BREZINSCHEK RI et al.: Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Europ. J. Haematol. (2002) 69(1):1-6.
84. BENVENUTO GM, LA VECCHIA L, MORANDI P et al.: Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors. Ital. Heart J. (2000) 1:1457-1463.
85. 2) cyclophosphamide. Bone Marrow Transpl. (2001) 28(3):277-282.
86. MACHACKOVÁ J, ADAMCOVÁ M, GERŠL V, HRDINA R, MAZUROVÁ Y, NOBILIS M: Evaluation of cardiac effects of the new antineoplastic drug - dimethoxybenfluron - on a rabbit model. Phys. Res. (2001) 50:491-499.
87. DELLA TORE P, PODESTA A, IMONDI AR et al.: PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential. Cancer Chemother. Pharmacol. (2001) 47(4):355-360.
88. FLECKENSTEIN A, JANKE V, DORING HJ: Myocardial fiber necrosis due to intracellular Ca overload, a new perception in cardiac pathophysiology. In: Myocardial biology. Dhalla NS (Ed.), Baltimore University Press, Baltimore (1974):563-580.
89. BLEUEL H, DESCHL U, BERTSCH T et al.: Diagnostic efficiency of troponin T measurements in rats with experimental myocardial cell damage. Exp. Toxicol. Pathol. (1995) 47:121-127.
90. BERTSCH T, BLEUEL H, AUFENANGER J, REBEL W: Comparison of cardiac troponin T and cardiac troponin I concentrations in peripheral blood during orciprenaline induced tachycardia in rats. Exp. Toxicol. Pathol. (1997) 49:467-468.
91. ADAMCOVÁ M, KOKŠTEIN Z, PALICKA V et al.: Cardiac troponin T in pregnant women having intravenous tocolytic therapy. Arch. Gynecol. Obstet. (1999) 62:121-126.
92. ADAMCOVÁ M, KOKŠTEIN Z, PALICKA V, VÁVROVÁ J, PODHOLOVÁ M, KOSTÁL M: Cardiac troponin T in neonates after acute and long-term tocolysis. Biol. Neonate (2000) 78(4):281-287.
93. LECHNER W, ARTNER DWORZAK E, SOLDER E: Tocolysis with magnesium, hexoprenalin-metoprolol and diltiazem - evaluation of cardiotoxic side-effects during troponin T. Magnesium-Bull. (1992) 14(1):12-14.
94. CHIANG VW, BURNS JP, RIFAI N, LIPSHULTZ SE, ADAMS MJ, WEINER DL: Cardiac toxicity of intravenous terbutaline for the treatment of severe asthma in children: A prospective assessment. J. Pediatr. (2000) 137(1):73-77.
95. PEDERSON KJ, KUNTZ DH, GARBE GJ: Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man. Canad. J. Cardiol. (2001) 17(5):599-601.
96. PATEL VB, AJMAL R, SHERWOOD RA, SULLIVAN A, RICHARDSON PJ, PREEDY VR: Cardioprotective effect of propranolol from alcohol-induced heart muscle damage as assessed by plasma cardiac troponin T. Alcohol. Clin. Exp. Res. (2001) 25(6):882-889.
97. DENISON H, JERN S, JAGENBURG R, WENDESTAM C, WALLERSTEDT S: ST-segment changes and catecholamine-related myocardial enzyme release during alcohol withdrawal. Alcohol Alcoholism (1997) 32(2):185-194.
98. MCLEURIN M, APPLE FS, HENRY TD et al.: Cardiac troponin I and T concentrations in patients with cocaine-associated chest pain. Ann. Clin. Biochem. (1996) 33:183-186.
99. KONTOS MC, ANDERSON FP, ORNATO JP, TATUM JL, JESSE RL: Utility of troponin I in patients with cocaine-associated chest pain. Acad. Emerg. Med. (2002) 9:1007-1013.
100. ERWIN MB, DELIARGYRIS EN: Cocaine-associated chest pain. Am. J. Med. Sci. (2002) 324(1):37-44.
101. KATUS HA, REMPPIS A, LOOSER S, HALLERMEIER K, SCHEFFOLD T, KUBLER W: Enzyme-linked immunoassay of cardiac troponin T for detection of acute myocardial infarction in patients. J. Mol. Cell. Cardiol. (1989) 21:1349-1353.
102. LARUE C, DEFACQUE-LACQUEMENT H, CALZOLARI C, LE NGUYEN D, PAU B.: New monoclonal antibodies as probes for human cardiac troponin I: Epitopic analysis with synthetic peptides. Mol. Immunol. (1992) 29:271-278.
103. LAURINO JP: Troponin I: An update on clinical utility and method standartization. An. Clin. Lab. Science (2000) 30(4):412-421.
104. KATUS HA, LOOSER S, HALLERMAYER K et al.: Development and in vitro characterization of a new immunoassay for cardiac troponin T. Clin. Chem. (1992) 38:386-393.
105. COLLINSON PO, BOA FG, GAZE DC: Measurement of cardiac troponins. Ann. Clin. Biochem. (2001) 38(5):423-449.
106. WU AHB: Analytical issues affecting the clinical performance of cardiac troponin assays. In: Markers in cardiology: Current and future clinical applications. Adams JE III (Ed.), Futura Publishing Company, Inc., Armonk, NY (2001):1-12.
107. VALDES R Jr., JORTANI SA: The current assessment of qualitative and quantitative point-of-care testing of cardiac markers. In: Markers in cardiology: Current and future clinical applications. Adams JE III (Ed.), Futura Publishing Company, Inc., Armonk, NY (2001):35-46.
108. PANTEGHINI M, PAGANI F, BONETTI G: The sensitivity of cardiac markers: An evidence-based approach. Clin. Chem. Lab. Med. (1999) 37(11/12):1097-1106.
109. WU AHB, APPLE FS, GIBLER WB, JESSE RL, WARSHAW MM, VALDES R Jr: National Academy of Clin. Biochem. Standards of Laboratory Practise: Recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem. (1999) 45:1104-1121.
110. MORJANA NA: Degeneration of human cardiac troponin I after myocardial infarction. Biotechnol. Appl. Biochem. (1998) 28:105-111,
111. KATRUKHA AG, BEREZNIKOVA AV, ESAKOVA TV et al.: Troponin I is released in blood stream of patients with acute myocardial infarction not in free form but as a complex. Clin. Chem. (1997) 43:1379-1385.
112. TATE JR, HEATHCOTE D, RAYFIELD J, HICKMAN PE: The lack of standardization of cardiac troponin I assay systems. Clin. Chim. Acta (1999) 284(2):141-149.
113. APPLE FS, QUIST HE, DOYLE PJ, OTTO AP, MURAMAKI MM: Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology American College of Cardiology consensus recommendations. Clin. Chem. (2003) 49(8):1331-1336.
114. WU AHB: Analytical issues and the evaluation of cutoff concentrations for cardiac markers. In Cardiac Markers. Wu AHB (Ed.) Humana Press, Inc., Totowa, NJ (2003):231-241.
115. GAO WD, ATAR D, LIU YG, PEREZ NG, MURPHY AM, MARBAN E: Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ. Res. (1997) 80(3):393-399.
116. MCDONOUGH JL, ARRELL DK, VAN EYK JE: Troponin I degradation and covalent complex formation accompanies myocardial ischemia/reperfusion injury. Circ. Res. (1999) 84(1):9-20.
117. HERMENS WTH: Mechanisms of protein release from injured heart muscle. In: Myocardial damage. Developments in Cardiovascular Medicine (vol. 205). Kaski JC and Holt DW (Eds.), Kluwer Academic publishers (1998):189-198.
118. MAIR J: Tissue release of cardiac markers: From physiology to clinical applications. Clin. Chem. Lab. Med. (1999) 37(11 /12): 1077-1084.
119. VAN DER LAARSE A: Hypothesis: Troponin degradation is one of the factors responsible for deterioration of left ventricular function in heart failure. Cardiovasc. Res. (2002) 56(1):8-14.
120. JAFFE AS, RAVKILDE J, ROBERTS R et al.: It's time for a change to troponin standard. Circulation (2000) 102:1216-1220.
121. REMPPIS A, SCHEFFOLD T, GRETEN J et al.: Intracellular compartmentation of troponin T: release kinetics after global ischemia and calcium paradox in the isolated perfused rat heart. J. Mol. Cell. Cardiol. (1995) 27(2):793-803.
122. CHILDS AC, PHANUEF SL, DIRKS AJ, PHILLIPS T, LEEUWENBURGH C: Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res. (2002) 62(16):4592-4598.
123. CHRISTIANSEN S, REDMANN K, SCHELD HH et al.: Adriamycin-induced cardiomyopathy in the dog - an appropriate model for research on partial left ventriculectomy. J. Heart Lung Transpl. (2002) 21:783-790.
124. JAFFE AS: Elevations in cardiac troponin measurements: false false-positives. The real truth. Cardiovasc. Toxicol. (2001) 1:87-92.
125. NOSANCHUK JS: False increases of troponin I attributable to incomplete separation of serum. Clin. Chem. (1999) 45:714.
126. PLEBANI M, MION M, ALTINIER S, GIROTTO MA, BALDO G, ZANINOTTO M: False-positive troponin I attributed to a macrocomplex. Clin. Chem. (2002) 48:677-678.
127. GERHARDT W, NORDIN G, HERBERT AK et al.: Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. Clin. Chem. (2000) 46:817-821.
128. STIEGLER H, FISCHER Y, VAZQUEZ-JIMENEZ JF et al.: Lower cardiac troponin T and I results in hepaxin-plasma than in serum. Clin. Chem. (2000)46:1338-1344.
129. KATRUKHA A, BEREZNIKOVA A, FILATOV V, ESAKOVA T: Biochemical factors influencing measurement of cardiac troponin I in serum. Clin. Chem. Lab. Med. (1999) 37(11/12):1091-1095.
130. NOUSIAINEN T, JANTUNEN E, VANNINEN E et al.: Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur. J. Haematol. (1999) 62:135-141.
131. SUZUKI T, HAYASHI D, YAMAZAKI T et al.: Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. (1998) 136:362-363.
132. HAYAKAWA H, KOMADA Y, HIRAYAMA M et al.: Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med. Pediatr. Oncol. (2001) 37:4-9.
133. DUNN MJ: Studying heart disease using the proteomic approach. Drug Discov. Today (2000) 5:76-84.
134. LABUGGER R, ARRELL DK, VAN EYK JE: Cardiac troponins: Exploiting the diagnostic potential of disease-induced protein modifications. In Cardiac Markers. Wu AHB (Ed.) Humana Press, Inc., Totowa, NJ (2003):125-138.
135. PETRIOCIN EF, RAJAPASKE V, HERMAN EH et al.: Toxicoproteomics: Serum proteomics pattern diagnostics for early detection of drug induced cardiac toxicides and cardioprotection. Toxicol. Pathol. (2004) 32(1):122-130.